

Ref no: 217111120
From: Commercial
Date: 11/11/20
Subject: Anti-VEFG treatments for eye conditions

REQUEST

I am analysing the usage of anti-VEFG treatments for eye conditions. I would greatly appreciate if you could answer two questions:

1. Within your trust how many patients over the last 12 months (November 2019 to October 2020 or latest available) have received the following anti-VEGF treatments:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizuma

RESPONSE

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.